Anthem Biosciences Limited (NSE: ANTHEM) and Onesource Specialty Pharma Limited (NSE: ONESOURCE) are both listed in the Pharmaceutical CDMO and CRO Services industry. Anthem Biosciences has a market capitalisation of ₹47,055 Cr and Onesource Specialty Pharma ₹17,868 Cr, as of 9 Nov 2026. Return on equity is 19.45% for Anthem Biosciences and -1.26% for Onesource Specialty Pharma. Over one year, Anthem Biosciences's share price is up 36.4% and Onesource Specialty Pharma's is down 14.1%.
| Metric | Anthem Biosciences | Onesource Specialty Pharma |
|---|---|---|
| NSE Symbol | ANTHEM | ONESOURCE |
| BSE Code | 544449 | 544292 |
| Share Price | ₹959.00 | ₹1,613.50 |
| Market Cap | ₹47,055 Cr | ₹17,868 Cr |
| P/E Ratio | 80.1 | Not meaningful (loss) |
| Return on Equity | 19.45% | -1.26% |
| Return on Assets | 14.20% | -0.03% |
| Dividend Yield | 0.24% | — |
| Beta (1Y) | 0.56 | 0.25 |
| 1-Year Price Change | +36.4% | -14.1% |
| 3-Month Price Change | +12.4% | +2.4% |
| 52-Week Range | ₹579.15 – ₹989.10 | ₹1,057.00 – ₹1,917.80 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹594 Cr | ₹516 Cr |
| Quarterly Net Profit | ₹211 Cr | ₹57 Cr |
| Net Margin | 35.6% | 11.1% |
| EPS (Basic, Quarter) | ₹3.75 | — |
| Results Basis | consolidated | consolidated |
| Headquarters | Bengaluru, Karnataka | Bengaluru, Karnataka |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Anthem Biosciences Limited operates as a contract research, development, and manufacturing organization in India, rest of Asia, North America, Europe, and internationally. It operates in two segments: Contract Manufacturing, Development & Discovery Services; and Speciality Ingredients. The company offers contract research development and manufacturing services, such as end-to-end services across the new chemical entity and new biological entity lifecycles, as well as engages in contract research, development, and manufacturing of development batches of molecules used for clinical trials up to …
OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Ireland, the United States, and internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of preclinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoin…
Anthem Biosciences has a market capitalisation of ₹47,055 Cr, against ₹17,868 Cr for Onesource Specialty Pharma as of 9 Nov 2026, about 2.6 times the size by market cap.
Anthem Biosciences has a return on equity of 19.45% and Onesource Specialty Pharma -1.26%.
Anthem Biosciences's share price is up 36.4% over one year and Onesource Specialty Pharma's is down 14.1%.
Anthem Biosciences reported revenue of ₹594 Cr and net profit of ₹211 Cr for Q2 FY27. Onesource Specialty Pharma reported revenue of ₹516 Cr and net profit of ₹57 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.